



Improving Human Life by Advancing  
the Field of Transplantation

## AST BOARD OF DIRECTORS 2013-2014

### PRESIDENT

Daniel R. Salomon, MD  
The Scripps Research Institute

### PRESIDENT-ELECT

Kenneth A. Newell, MD, PhD  
Emory University

### IMMEDIATE PAST-PRESIDENT

Roslyn B. Mannon, MD  
University of Alabama at Birmingham

### TREASURER

Kimberly Ann Brown, MD  
Henry Ford Hospital

### SECRETARY

Anil Chandraker, MD, FRCP  
Brigham and Women's Hospital

### COUNCILORS-AT-LARGE

James S. Allan, MD, MBA  
Massachusetts General Hospital

Rita R. Alloway, PharmD  
University of Cincinnati

Ronald G. Gill, PhD  
University of Colorado, Denver

Michael G. Ison, MD, MS  
Northwestern University

Paul Martin, MD  
University of Miami

Dianne B. McKay, MD  
University of California, San Diego

Larry B. Melton, MD, PhD  
Baylor Medical Center, Dallas

David P. Nelson, MD  
Integrus Baptist Medical Center of Oklahoma

Thomas Pearson, MD, DPhil  
Emory University

### EXECUTIVE VICE PRESIDENT

Susan J. Nelson, CAE

### EXECUTIVE DIRECTOR

Libby McDannell, CAE

Monday, February 17, 2014

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Rm. 1061  
Rockville, MD 20852

Re: Docket No. FDA-2013-D-1358 – **Draft Guidance for Industry: Recommendations for Premarket Notification (510(k) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Transfusion and Transplantation**

To Whom It May Concern:

On behalf of the American Society of Transplantation (AST), representing the majority of professionals engaged in the field of organ transplantation, I write to you in full support of the attached comments from the American Society for Histocompatibility and Immunogenetics (ASHI) regarding the Food and Drug Administration's (FDA) recent draft guidance for industry Docket No. FDA-2013-D-1358.

AST is concerned that the FDA's recent draft guidance (as currently drafted and proposed) will significantly delay the use of newly available HLA allele information in transplant decision making. AST joins ASHI in requesting that the FDA amend the draft guidance to ensure that patient care is not negatively impacted by what appears to be unintended consequences of the proposal as currently drafted.

Thank you in advance for your consideration of our request. If you have any questions, please do not hesitate to contact me directly.

Best Regards,

Daniel Salomon, MD  
President, American Society of Transplantation

### NATIONAL OFFICE

15000 Commerce Parkway, Suite C • Mt. Laurel, NJ 08054  
856.439.9986 • Fax: 856.439.9982 • info@myAST.org • www.myAST.org

### GOVERNMENT RELATIONS

William Applegate, Director of Government Relations • Bryan Cave, LLP  
1155 F Street, NW • Washington, DC 20004  
202.258.4989 • bill.applegate@bryancave.com

### WORLD TRANSPLANT CONGRESS 2014

July 26–31, 2014  
San Francisco, CA